Development, production, and sales of companion diagnostics

Overview

More than 300 kinds of development of a FISH probe, production and sale are being performed from 200,000 kinds of BAC clone built originally.
The product in which the cancer relation, genetic abnormal of diagnosis preimplantation and regenerative medicine (iPS cell) are detected has been often developed.
These products are also used by foreign countries, not only the country and appear on a paper beyond 120 reports.

Sales of reagents, clinical test drugs, industrial medicine, and equipment for clinical trials and chemistry use

Conducting a consulting business in the field of medicine

Development of endoscopic cancer treatment equipment using laser

NGS and miRNA-based biomarker screening to Cancer-free world by Mirxes

Overview

MiRXES is a biotech company founded by researchers from National University of Singapore. The company was incubated and spun off from Agency of Science Technology and Research (A*STAR) Singapore. The ID3EALTM technology provides high sensitivity and specificity for miRNA detection using qRT-PCR. MiRXES has developed early cancer detection IVD kits and LDT service named GASTROClearTM for gastric cancer and LUNGClearTM for lung cancer with human blood, and spread the products with Fortitude Kit (COVID-19 detection kit) in global market. MiRXES also recently invested in developing Genomics capacity, with NGS devices and bioinformatics team for further R&D project named CADENCE, which aimed to develop the effective and affordable multi-cancer screening test. MiRXES Japan was incorporated in 2020, providing life science solutions such as miRNA and NGS products and services to Japan. MiRXES Japan also continues to establish clinical collaborations for optimization and validation of our cancer early detection for commercialization in Japan.

R&D of medical mini-robot including self-propelling capsule endoscopy

Overview

MU Ltd. was founded in 2011 to realize the self-propelling capsule endoscopy nicknamed “MiniMermaid” with individual and continued 20 years development at an university.
The system will be a pioneer of painless medical mini-robot capable of moving freely in a body and conducting medical treatment of digestive tract.
Applying “MiniMermaid” technology, we have developed an aquatic mini drone to swim freely in 3-D space under water.

R&D, production and sale of biochips

Overview

The biochip technology of MYTEC can detect the substance of a very very small quantity molecular level in a short time. It was the first in the world to success is effective to adsorb specifically protein biochip surface "quantum crystal," "peroxide meso silver crystal" (3-dimensional self-assembled crystal) produced.
Simple, rapid, epigenetic analysis Proteo ® chip is the "new biochip".

Production and sales of radioactive pharmaceuticals

Overview

Nihon Medi-Physics Co., Ltd. is in a leading position in the manufacture and distribution of radiopharmaceuticals, which play an important role for diagnosis of cerebral vascular disorder, dementia, heart disease and cancer. Recognizing our mission as seeking novel value to nuclear medicine through our effort to develop new product and technology, we provide contracted services of labeling existing or new drug candidate substances with radioisotopes. Through such services, we support non-clinical/clinical studies of pharmaceutical companies in patients screening and in evaluating clinical outcome of new drug candidates. We aim at materializing “Theranostics (therapeutics and diagnostics combined)” by nuclear medicine and determine to continue contribution to further advancement of medical care.

R&D of medicine

Overview

Unique drug discovery and development standing on virology.
We do our business activities of pharmaceutical and diagnostic businesses together under the concept of "drug discovery and development standing on virology".
In pharmaceutical business, we will develop safe, effective and novel drug targeting "cancer and serious infectious diseases" that can be a new option of therapy for such intractable diseases. In diagnostic business, we will provide new inspection services using genetic modification technology for virus that is our platform technology. We will establish multiple earning structures based on the achievement by the activities above, and accelerate the development of current new drug candidates under more stable management environment. In addition, we will actively seek or obtain seeds for new drugs to continue and expand our business for the future.